Rocket Pharmaceuticals
RCKT
148 hedge funds and large institutions have $1.38B invested in Rocket Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 58 increasing their positions, 44 reducing their positions, and 21 closing their positions.
3,600% more call options, than puts
Call options by funds: $74K | Put options by funds: $2K
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
1.92% more ownership
Funds ownership: 96.21% → 98.13% (+1.9%)
1% more funds holding
Funds holding: 146 → 148 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
25% less capital invested
Capital invested by funds: $1.85B → $1.38B (-$470M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$28.3M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$13.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.7M |
| 4 |
Barclays
London,
United Kingdom
|
+$6.51M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
+$6.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$33.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.9M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$12.1M |
| 4 |
PA
Perceptive Advisors
New York
|
-$9.58M |
| 5 |
Goldman Sachs
New York
|
-$8.26M |
RCKT Hedge Fund Activity: Q4 2021 in Review
148 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2021, worth a combined $1.38B — down 25% from $1.85B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RCKT positions and 21 closed out — a net gain of 4 holders — while 58 added to existing stakes and 44 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $28.3M. The largest seller was Janus Henderson Group, cutting an estimated $33.1M.
- 148 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2021, up from 146 in Q3 2021.
- Funds reported $1.38B of Rocket Pharmaceuticals stock for Q4 2021, down 25% quarter-over-quarter.
- 25 funds opened new Rocket Pharmaceuticals positions in Q4 2021 and 21 closed out, a net change of +4 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2021 was Morgan Stanley, an estimated $28.3M added.
- The largest Rocket Pharmaceuticals seller in Q4 2021 was Janus Henderson Group, an estimated $33.1M sold.
Based on aggregated 13F filings for Q4 2021.